One-year follow-up results of atrial fibrillation patients who undergoing transcatheter aortic valve implantation.
10.3760/cma.j.cn112148-20211124-01016
- VernacularTitle:心房颤动患者经导管主动脉瓣植入术后1年随访结果
- Author:
Shi Chen ZHOU
1
;
Kai XU
1
;
Bin WANG
1
;
Geng WANG
1
;
Zhen Yang LIANG
1
;
Yang LI
1
;
Yi FANG
1
;
Ling Fei ZHENG
1
;
Yan Qiu WANG
1
;
Wei Wei ZHOU
1
;
Quan Min JING
1
;
Ya Ling HAN
1
Author Information
1. Department of Cardiology, General Hospital of Northern Theater Command, Shenyang 110016, China.
- Publication Type:Journal Article
- MeSH:
Aged;
Aged, 80 and over;
Anticoagulants;
Aortic Valve;
Aortic Valve Stenosis/surgery*;
Atrial Fibrillation/drug therapy*;
Follow-Up Studies;
Humans;
Male;
Retrospective Studies;
Risk Factors;
Transcatheter Aortic Valve Replacement;
Treatment Outcome
- From:
Chinese Journal of Cardiology
2022;50(2):132-136
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To investigate whether atrial fibrillation (AF) before transcatheter aortic valve implantation (TAVI) will affect the prognosis of patients post TAVI. Methods: This is a single center retrospective study. A total of 115 patients with severe aortic stenosis (AS) who were admitted to General Hospital of Northern Theater Command from May 2016 to November 2020 and successfully received TAVI treatment were included. According to absence or accompaniment of AF pre-TAVI, they were divided into AF group (21 cases) and non-AF group (94 cases). The patients were followed up for postoperative antithrombotic treatment and the occurrence of the net adverse clinical and cerebrovascular events (NACCE) at 12 months post TAVI, including cardiogenic death, readmission to hospital for heart failure, nonfatal myocardial infarction, ischemic stroke and severe bleeding (BARC levels 3-5). Univariate logistic regression was used to analyze the related factors of NACCE. Results: Among the 115 selected patients, age was (73.8±6.9) years, there were 63 males. And 21 cases (18.2%) were diagnosed as AFbefore TAVI. In terms of postoperative antithrombotic therapy, 48.9% (46/94) of the patients in the non-AF group received monotherapy and 47.9% (45/94) received dual antiplatelet therapy. In the AF group, 47.6% (10/21) received anticoagulants and 33.3% (7/21) received dual antiplatelet therapy. The proportion of patients in the AF group taking non-vitamin K antagonist oral anticoagulants (NOAC) was higher than that in the non-AF group (38.1% (8/21) vs. 2.1% (2/94), P<0.001). Patients in both groups were followed up to 12 months after TAVI. During the 12 months follow-up, the incidence of NACCE after TAVI was 14.3% (3/21) in the AF group, which was numerically higher than that in the non-AF group (6.4% (6/94)), but the difference was not statistically significant (P=0.441). The incidence of severe bleeding was significantly higher in the AF group than in the non-AF group (9.5% (2/21) vs. 0, P=0.032). Univariate logistic regression analysis showed that hypertension was associated with the risk of NACCE (OR=8.308, P=0.050), while AF was not associated with the risk of NACCE (P=0.235). Conclusion: The incidence of severe bleeding after TAVI is higher in patients with AF than in patients without AF prior TAVI, and there is a trend of increased risk of NACCE post TAVI in AF patients.
